Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/123848
Distinct behaviour of sorafenib in experimental tumours inducing cachexia: the role of STATS3.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The presence of a tumour is very often associated with wasting in the host, affecting both skeletal muscle and adipose tissue. In the present study we used sorafenib, a multi-kinase inhibitor with anti-tumour activity, in order to investigate the effects of chemotherapy on wasting. Three different experimental mouse tumour models were included: C26 colon carcinoma, B16 melanoma and Lewis lung carcinoma (LLC). The results obtained clearly show that sorafenib was effective in reducing tumour growth in LLC and B16 models, while it had no effect on C26. Interestingly, sorafenib treatment reduced the signs of muscle wasting and improved the physical activity in the LLC model and also in the C26, despite the absence of antineoplastic action in the latter. Our results discard a role for IL-6 in the action of sorafenib since the drug did not affect the levels of this cytokine. Conversely, sorafenib seems to act by influencing both STAT3 and ERK activity at muscle level, leading to reduced accumulation of Pax7 and atrogin-1. Sorafenib may interfere with muscle wasting by decreasing the activation of these signal transduction pathways.
Matèries
Matèries (anglès)
Citació
Citació
TOLEDO SOLER, Miriam, PENNA, Fabio, BUSQUETS RIUS, Sílvia, LÓPEZ-SORIANO, Francisco j., ARGILÉS HUGUET, Josep ma.. Distinct behaviour of sorafenib in experimental tumours inducing cachexia: the role of STATS3.. _PLoS One_. 2014. Vol. 9, núm. 12, pàgs. 1-16. [consulta: 24 de gener de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/123848]